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Abstract
Ornithine decarboxylase (ODC) antizyme inhibitor 2 (AZIN2), originally called ODCp, is a
regulator of polyamine synthesis that we originally identified and cloned. High expression of
ODCp mRNA was found in brain and testis. We reported that AZIN2 is involved in regulation
of cellular vesicle transport and / or secretion, but the ultimate physiological role(s) of AZIN2
is still poorly understood. In this study we used a peptide antibody (K3) to human AZIN2 and
by immunohistochemistry mapped its expression in various normal tissues. We found high
expression in the nervous system, in type 2 pneumocytes in the lung, in megakaryocytes, in
gastric parietal cells co-localized with H,K-ATPase beta subunit, in selected enteroendo-
crine cells, in acinar cells of sweat glands, in podocytes, inmacula densa cells and epithe-
lium of collecting ducts in the kidney. The high expression of AZIN2 in various cells with
secretory or vesicle transport activity indicates that the polyamine metabolism regulated by
AZIN2 is more significantly involved in these events than previously appreciated.
Introduction
The polyamines, putrescine, spermidine and spermine are organic polycations known to be
involved in regulation of many fundamental cellular functions like proliferation, differentia-
tion, malignant transformation and apoptosis [1,2]. The ultimate molecular mechanism(s) by
which polyamines exert their activity is still however incompletely understood [3]. Ornithine
decarboxylase (ODC), which decarboxylates ornithine to generate putrescine, is the rate-limit-
ing enzyme of polyamine synthesis. Elevated ODC activity is typically found in rapidly prolifer-
ating cells and in neoplastic tissue. ODC is a transcriptional target of the c-myc oncogene [4]
but has also itself oncogenic properties. We originally reported that overexpression of human
ODC cDNA in NIH3T3 cells induced their malignant transformation [5] with ability to form
tumors in athymic mice [6]. Given the cellular impact of ODC its activity is under strict
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transcriptional and posttranslational regulation [7]. A sizeable portion of cellular ODC is
bound as catalytically inactive monomers to proteins called antizymes (AZ) [8,9]. Four mem-
bers of human antizymes have been identified out of which AZ1 is ubiquitously expressed.
AZ1 directs ODC for proteosomal degradation independently of ubiquitination and also inhib-
its cellular uptake of polyamines.
Antizyme inhibitors (AZIN) are AZ antagonists. They are homologous to ODC but devoid
of catalytic activity. Monomeric AZINs bind AZs with higher affinity than ODC thereby releas-
ing sequestered ODC to form catalytically active dimers [8,10]. In addition to releasing ODC
the binding of AZ by AZIN may also reduce the degradation of ODC.
AZIN, now called AZIN1, was first identified in 1982 by Fujita et al. [11] Accumulated data
indicate that AZIN1 is functionally linked to normal and malignant cell proliferation. Forced
overexpression of AZIN1 in NIH3T3 cells induces malignant transformation like that seen
with overexpression of ODC [12]. Gene amplifications of AZIN1 have been found in various
human neoplasms including cancer in the breast, ovary and prostate [13].
We originally identified and cloned the second form of AZIN initially called ODC paralog
(ODCp). ODCp was found to potentially occur in at least eight alternative spliced forms. The
highest levels of ODCp mRNA was found in the brain and testis. Since we noticed that cysteine
360, which is critical for ODCs catalytic activity, was substituted by valine in ODCp we sug-
gested in the original report that ODCp represents a novel form of ODC antizyme inhibitor
[14]. The antizyme inhibitory activity of ODCp was subsequently demonstrated in mouse [15]
and human [15,16] and is now called AZIN2.
Physiologically, AZIN2 appears most abundantly in differentiated resting cells or in cells
with slow turnover. By immunohistochemistry we found robust expression of AZIN2 in the
brain along the neural axons and dendrites in a granular or vesicular pattern [17]. An intrigu-
ing finding was the elevated expression of AZIN2 in the brain of Alzheimer patients. This may
be of relevance for higher content of polyamines present in the brain in Alzheimer’s disease
[18].
The antibody used for staining of AZIN2 in the brain reacted mainly with Leydig cells in
normal testis with only weak reactivity in the germinal epithelium [19].
By the use of a temperature-sensitive mutant of viral glycoprotein, VSVG3ts045, we showed
that intact AZIN2 regulates intracellular vesicle transport in MCF/7 breast cancer cells [20].
We also reported expression of AZIN2 in human normal mast cell and mastocytomas.
Downregulation of AZIN2 expression in mast cell selectively blocked stimulated release of
serotonin without appreciable effect on histamine release [21].
Lopez-Garcia et al. created AZIN2 hypomorphic mice and found evidence for regulatory
influence of AZIN2 on secretion of insulin from pancreatic islets [22].
To obtain a comprehensive view of the distribution of AZIN2 in human cells and tissues we
used AZIN2 peptide antibodies made in rabbits and mapped its endogenous expression by
immunohistochemistry.
Materials and Methods
Paraffin blocks containing normal human tissues were collected from the archives of the
Department of Pathology of University of Helsinki and HUSLAB according to the local legisla-
tion. The study was approved by the Surgical Ethics Committee of Helsinki University Hospital
(Dnro HUS 226/E6/06, extension TMK02 §66 17.4.2013), and the National Supervisory
Authority of Welfare and Health (Valvira Dnro 10041/06.01.03.01/2012). Freshly cut 4-μm tis-
sue sections were deparaffinized in xylene and rehydrated through a gradually decreasing con-
centration of ethanol to distilled water. Slides were treated in a PreTreatment module (Lab
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Vision Corp., Fremont, CA, USA) in Tris-EDTA (pH 9) buffer for 20 min at 98°C for antigen
retrieval. Immunohistochemical staining of sections was performed in an Autostainer 480 (Lab
Vision Corp., Fremont, CA, USA) by the Dako REAL EnVision Detection system, Peroxidase/
DAB+, Rabbit/Mouse (Dako, Glostrup, Denmark). Sections were incubated with anti-AZIN2
antibody (K3) for one hour at room temperature. In situ hybridization with sense and anti-
sense AZIN2 cRNA probes was performed using a Ventana Discovery Stainer Platform for
automated hybridization. The design and making of the diogenine-UTP labeled cRNA probes
and visualization of the hybridization have been described in detail [17,19].
We raised rabbit antibodies to different peptides representing unique portions of the AZIN2
molecule [17,19,21]. In this study we have used antibody K3 that was made against a peptide
(STRDLLKELTLGASQATT) representing the amino acids 18–35 of AZIN2. Branched pep-
tides were synthesized with an automated multiple peptide synthesizer (MultiPep; Intavis Bioa-
nalytical Instruments AG, Cologne, Germany) using Fmoc-chemistry and purified with HPLC
using a Supelco Discovery Biowide Pore C18 column (Supelco, Bellefonte, PA, USA). The
main peak was collected, lyophilized and used as antigens for immunizations. The antibody
was produced at the Viikki Laboratory Animal Centre, University of Helsinki, Finland. All ani-
mals were handled in strict accordance with good animal practice as defined by the relevant
Finnish animal welfare bodies, and the European Communities Council directive (86/609/
EEC). All animal work was approved by the Animal Experiment Board of the State Provincial
Office of Southern Finland (Reference number HY176-02) in accordance with national legisla-
tion. Validation of the specificity of the antibody called K3 has been reported [17,19,21]. The
antibody showed no cross-reactivity with ODC or with AZIN1 [17,19,21]. The K3 antibody
was used at a dilution of 1:500–1:800 for immunohistochemistry and 1:150 for indirect immu-
nofluorescence. Pre-immune serum from the same rabbit was used as negative control. The
antibodies used for immunohistochemistry and indirect immunofluorescence are listed in
Table 1.
Photographs of IHC stained sections were taken with an Olympus BX51 microscope
equipped with a Nikon DS-U1 camera. IF stainings were photographed with a Zeiss Axiophot2
microscope or with a Leica SP2 confocal microscope.
Results
The Nervous System
We have previously reported robust expression of AZIN2 in the brain distributed along neural
axons and dendrites in a granular or vesicular pattern [17]. While antibody K3 stained
Table 1. Antibodies for immunohistochemistry (IHC) and immunofluorescence (IF).
Antibody Clone Company Pre-treatment Dilution
A. Primary antibodies.
K3 Rabbit in-house Tris-HCL (pH 8.5) 1:500–1:800 (IHC) 1:150 (IF)
H,K-ATPase mAb 2B6 MBL International Citrate (pH 6.0) 1:100 (IHC) 1:30 (IF)
Serotonin mAb 5HT-H209 DAKO Citrate (pH 6.0) 1:20 (IF)
WT1 mAb WT1-562 Novocastra Citrate (pH 6.0) 1:20 (IF)
Chromogranin A mAb 319 Upstate Millipore Citrate (pH 6.0) 1:30 (IF)
Rab27b Rabbit 13412-1-AP Proteintech Citrate (pH 6.0) 1:400 (IHC)
B. Secondary antibodies for indirect immunoﬂuorescence.
Donkey-anti-rabbit, Alexa Fluor1 555 conjugate A31572 Invitrogen 1:1000
Donkey-anti-mouse, Alexa Fluor1 488 conjugate A21202 Invitrogen 1:1000
doi:10.1371/journal.pone.0151175.t001
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dendrites and axons in the CNS somas of nerve cell bodies in spinal ganglions showed strong
reactivity (Fig 1a). The presence of AZIN2 mRNA was confirmed by in situ hybridization (Fig
1c). Also the myenteric (Auerbach0s) nerve plexuses in the intestinal wall stained with antibody
K3 (not shown). Staining patterns with K3 antibody in the brain stem (Fig 1e) and cerebellum
(Fig 1f) are shown.
Hematopoietic Cells
In addition to our previously reported expression of AZIN2 in normal mast cells and in masto-
cytomas [21] we found AZIN2 in a slightly granular distribution in cytoplasm of megakaryo-
cytes of normal bone marrow (Fig 2). Positive staining was also seen in aggregates of platelets
and in mast cells / basophils.
The Stomach
A strong staining of AZIN2 in a tubular pattern was found in the parietal cells of normal gastric
mucosa (Fig 3a). A staining of corresponding distribution was seen with a mAb to the H,
K-ATPase beta subunit (Fig 3b). Confocal microscopy of double immunofluorescence staining
showed co-distribution of AZIN2 and H,K-ATPase (Fig 3c–3e).
Fig 1. Expression of AZIN2 in neural tissue. Nerve cells in a spinal ganglion stained with K3 (a) and control
staining with pre-immunization serum from the same rabbit (b). In situ hybridization with sense RNA probe (c)
and anti-sense (control) probe (d). Staining of a portion of Nucleus dentatus (e) and of the granular cell layer
in cerebellum (f).
doi:10.1371/journal.pone.0151175.g001
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Enteroendocrine Cells
A proportion of enteroendocrine cells, particularly in the small intestine, showed strong stain-
ing for AZIN2 (Fig 4a). Double immunofluorescence with a mAb to the marker for enteroen-
docrine cells Chromogranin A (ChrA) revealed that about every third ChrA-positive cell co-
stained for AZIN2 (Fig 4b–4d). Given our earlier finding that AZIN2 regulates secretion of
serotonin but not of histamine from mast cells we performed a double immunofluorescence
staining with a mAb to serotonin. Serotonin-positive enteroendocrine cells were seen but co-
Fig 2. Expression of AZIN2 in megakaryocytes in normal bonemarrow. Insert: A megakaryocyte at
higher magnification showing a granular cytoplasmic staining.
doi:10.1371/journal.pone.0151175.g002
Fig 3. Staining of normal gastric mucosa (corpus). AZIN2 reactivity in a tubular pattern in parietal cells
(insert) (a). A consecutive section stained with mAb to H,K-ATPase revealed a similar distribution (b).
Confocal microscopy of double immunofluorescence staining of AZIN2 (e) and H,K-ATPase (c) show co-
distribution in the merged picture (d).
doi:10.1371/journal.pone.0151175.g003
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expression with AZIN2 was not detected (not shown). The endocrine product(s) elaborated by
the AZIN2-positive cells in the intestinal mucosa remains to be identified.
The Lung
A robust expression of AZIN2 was found in type 2 alveolar pneumocytes that generate surfac-
tant. No staining of AZIN2 was seen in type 1 alveolar pneumocytes (Fig 5a and 5b). The acinar
epithelium of bronchial submucosal glands was negative while positive staining was seen in the
ductal epithelium (Fig 5c).
The bronchial mucosa showed expression of AZIN2. A heterogenic staining pattern could
be appreciated with particularly strong staining of the stalks of goblet cells while the content of
the goblets remained negative (Fig 5d and 5e). Some distinctly staining cells close to the basal
membrane were also seen. They may represent neuroendocrine (Kulchitshy) cells but identifi-
cation of their phenotype needs additional studies.
Exocrine Glands
The acinar, sweat-producing cells of normal sweat gland stained strongly for AZIN2. Viewing
at high magnification revealed a granular cytoplasmic distribution of AZIN2. The epithelial
cells of the ductal portion of the gland remained negative (Fig 6a).
Staining of breast tissue from non-lactating fertile women with morphological features of
early luteal phase revealed weak staining of lobular epithelium with some more intensively
stained individual cells in the ductal portions (Fig 6b). No appreciable expression of AZIN2
was seen in lobular epithelial cells of breast tissue representing an early follicular phase (not
shown). The acinar cells of lacrimal glands showed positive staining (Fig 6c) with a distribution
like that seen for the secretory G-protein Rab27b (Fig 6d).
Fig 4. Enteroendocrine cells of the duodenal mucosa express AZIN2 (a) (insert at higher magnification).
Double immunofluorescence staining with K3 (b) and mAb to ChrA (d) revealed a proportion of cells co-
expressing AZIN2 and ChrA while some ChrA-positive cells remained negative for AZIN2 (merged picture c).
doi:10.1371/journal.pone.0151175.g004
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The Kidney
A staining pattern corresponding to collecting ducts and glomeruli was seen in the kidney (Fig
7a). A heterogeneous staining intensity of individual cells was seen among the epithelial cells of
colleting ducts (Fig 7b–7d). The phenotype of these cells remains to be characterized with addi-
tional markers.
Fig 5. Expression of AZIN2 in type 2 pneumocytes (a, b black arrow) while type 1 pneumocytes are
negative (a, b red arrow). Ductal epithelium of bronchial submucosal glands show strong staining in
comparison to the acinar cells (c). Staining of AZIN2 in the mucosa of a large bronchus (d) and a smaller
bronchus (e).
doi:10.1371/journal.pone.0151175.g005
Fig 6. Expression of AZIN2 in exocrine glands. The sweat-producing acinar epithelium of a normal sweat
gland shows strong AZIN2 expression while the ductal cells (upper right corner) are negative (a). Lobular and
ductal epithelium in non-lactating breast shows a weak reactivity (b). Tear gland epithelium shows AZIN2
positivity (c) in a distribution similar to that seen for Rab27b (d).
doi:10.1371/journal.pone.0151175.g006
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AZIN2-positive cells were present in the glomeruli. The epithelium of cortical proximal
tubuli remained negative (Fig 8a). The distribution of the glomerular staining pattern suggested
AZIN2 expression in podocytes. To identify the phenotype of the positively staining cells we
performed double immunofluorescence with K3 antibodies and a mAb to WT1 as a nuclear
marker of podocytes. A majority of the glomerular cells with cytoplasmic staining for AZIN2
also showed nuclear expression WT1 identifying them as podocytes (Fig 8 insert). The special-
ized juxtaglomerular epithelial cells ofmacula densa in cortical ascending tubuli showed a
strong staining for AZIN2 (Fig 8a).
Discussion
There are no previous reports on systematic mapping of the expression of AZIN2 protein in
human tissues. The immunohistochemistry shown in this study is mainly based on an antibody
called K3 that reacts with the splicing variants of AZIN2 containing exons 1 and 2. Given the
high number of potential splicing variants [14] there may be tissues and cells expressing alter-
native splice variants not reactive with this antibody. In fact we found evidence for the expres-
sion of differently spliced forms of AZIN2 in the grey and white brain matter corresponding to
the somas and dendrites of pyramidal neurons in brain neocortex [17]. This finding suggests
that alternative splicing may guide compartmentalized targeting of AZIN2 expression.
The findings reported here show high physiological expression levels of AZIN2 in differenti-
ated cells that display secretory activity or endowed with the molecular machinery needed for
Fig 7. Staining pattern for AZIN2 in kidney corresponding to glomeruli and collecting ducts (a-c). Higher
magnification shows variable staining intensity in adjacent epithelial cells of collecting ducts (d,).
doi:10.1371/journal.pone.0151175.g007
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intracellular vesicle transport. This is particularly evident in acinar epithelium of sweat glands
and in type 2 pneumocytes.
We found a strong expression of AZIN2 in gastric parietal cells co-localizing with the H,
K-ATPase. The transport and secretion of gastric acid involves an intricate vesicular trafficking
machinery. This includes several members of the Rab family of GTPases [23], SNARE proteins
and secretory carrier membrane proteins. In addition to a regulatory influence on the vesicle
transport it is tempting to speculate, that AZIN2 locally activates ODC that by decarboxylation
of ornithine generates CO2 and hereby provides CO2 required for production of gastric acid
[24].
The expression of AZIN2 in podocytes is in agreement with previous studies showing active
release of vesicles from podocytes in the urine [25]. Impairment of vesicle trafficking by tar-
geted deletion of the vacuolar sorting protein 34 in mouse podocytes has been shown to cause
glomerulosclerosis [26] indicating the importance of an intact vesicle transport, where AZIN2
may be functionally involved.
The high epithelium in distal tubuli formingmacula densa displayed a particularly robust
staining. The cells sense changes in the NaCl concentration in the distal tubulus and elaborate
prostaglandins that trigger release of renin from juxtaglomerular cells to regulate the glomeru-
lar filtration rate [27].
There was heterogenic staining intensity of AZIN2 in epithelial cell of collecting ducts.
Whether the strongly staining cells are intercalated cells known to be rich in cytoplasmic vesi-
cles [28] and the faintly staining cell principal cells remains to be established. Another possibil-
ity is that staining intensity mere reflects actual activity of the secretory or transport machinery
of individual epithelial cells.
Viewing at high resolution revealed that the intracellular distribution of AZIN2 appears fre-
quently in a granular or vesicular pattern. This is indicative of a spatial association between
AZIN2 and secretory vesicles. The molecular mechanism(s) by which AZIN2 regulate vesicle
transport remains to be elucidated. It appears however that local regulation of the catalytic
activity of ODC and polyamine synthesis in distinct intracellular compartments is of
Fig 8. Selected glomerular cells show AZIN2 positivity. The high epithelium ofmacula densa (black
arrows) contains abundantly of AZIN2 while proximal tubules (PT) are negative. Insert: Double
immunofluorescence shows glomerular cells with cytoplasmic AZIN2 expression (red) and nuclear WT1
expression (green, white arrows). (Bright green background fluorescence in erythrocytes).
doi:10.1371/journal.pone.0151175.g008
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importance. Small G-proteins, particularly of the large Rab family, are well-established regula-
tors of vesicle transport [23].
We have previously reported evidence for compartmentalized activation of ODC during cell
transformation and activation. We found that ODC activity regulates the intracellular traffic of
RhoA during v-src-induced cell transformation. Locally generated putrescine activates RhoA
via transglutaminase-catalyzed polyamination [29]. Since the ODC activity during cell trans-
formation and proliferations is preferentially regulated via AZIN1 it is tempting to speculate
that AZIN2 upregulates ODC activity in distinct subcellular compartments to yield polyamines
that activate G-proteins of the Rab family via similar mechanisms. This hypothesis is currently
under investigation.
The purpose of this report is to map the physiological expression of AZIN2 in selected nor-
mal cell and tissues. The main message indicates that polyamine metabolism regulated by
AZIN2 plays a more compelling role in cellular secretory activity and /or vesicle transport than
previously appreciated.
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